Results 251 to 260 of about 307,381 (359)

Progressive Systemic Sclerosis

International Journal of Clinical Practice, 1964
openaire   +2 more sources

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell‐Targeted Therapies

Arthritis &Rheumatology, Accepted Article.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Racial and ethnic associations with interstitial lung disease and healthcare utilization in patients with systemic sclerosis. [PDF]

Rheumatology (Oxford)
Tukpah AC, Rose JA, Seger DL, Dellaripa PF, Hunninghake GM, Bates DW.   +5 more
europepmc   +1 more source

National Mortality Databases to Assess Disease Burden in Systemic Autoimmune Diseases: A Valuable Resource, But with Limitations

Arthritis &Rheumatology, Accepted Article.
Disease‐specific mortality statistics are useful measures of disease burden. Population‐based studies from a few United States counties have reported mortality in systemic autoimmune diseases (SAID). However, due to substantial differences in the population structure of these counties as well as relatively small numbers of SAID deaths in these counties,
Ram Raj Singh
wiley   +1 more source

Clinical characteristics and treatment patterns of systemic sclerosis patients in China: a single-center retrospective study. [PDF]

Clin Exp Med
Tian X, Li W, Li Y, Liang C, Zhang P, Xu T, Li L, Zuo W, Zhang B.   +8 more
europepmc   +1 more source

Distinct effects of complement C4A and C4B copy number in Systemic Sclerosis serological and clinical subtypes

Arthritis &Rheumatology, Accepted Article.
Objective Complement component 4 (C4), encoded by C4A and C4B within the major histocompatibility complex (MHC) on chromosome 6, regulates the immune response and clears immune complexes. Variable copy number (CN) of C4 genes and retroviral HERV‐K element influence its function.
Javier Martínez‐López, Carlos Rangel‐Peláez, Inmaculada Rodriguez‐Martin, Alfredo Guillen‐Del‐Castillo, Carmen P Simeón‐Aznar, José L Callejas, International SSc Group; PRECISESADs Clinical Consortium, Oliver Distler, Susanna M Proudman, Mandana Nikpour, Australian Scleroderma Interest Group (ASIG), Nicolas Hunzelmann, Gianluca Moroncini, Jeska K de Vries‐Bouwstra, Ariane L Herrick, Yannick Allanore, Marta E. Alarcon‐Riquelme, Lorenzo Beretta, Shervin Assassi, Christopher P Denton, Maureen D Mayes, Javier Martin, Marialbert Acosta‐Herrera, Martin Kerick   +23 more
wiley   +1 more source

Digital Gangrene and Postoperative Survival Following Lung or Heart-Lung Transplantation in Patients With Systemic Sclerosis. [PDF]

ACR Open Rheumatol
Lee BS, Melehani JH, Li S, Mooney J, Chung L.   +4 more
europepmc   +1 more source

Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation

Arthritis &Rheumatology, Accepted Article.
Background Beyond its role as a ribosome‐targeting antibiotic, linezolid was recently shown to modulate immune responses by inhibiting mitochondrial translation. Since mitochondrial dysfunction is implicated in various fibrotic diseases, including systemic sclerosis (SSc), this study aimed to evaluate the antifibrotic potential of linezolid and ...
Xuezhi Hong, Yanhua Xiao, Haodong Qi, Shihao Zhu, Tim Filla, Andrea‐Hermina Györfi, Yi‐Nan Li, Meilin Xu, Langxian Zhi, Thuong Trinh‐Minh, Clara Dees, Georg Schett, Jörg H.W. Distler, Alexandru‐Emil Matei   +13 more
wiley   +1 more source

An Unusual Case of Seronegative Systemic Sclerosis and Cardiac Tamponade. [PDF]

Cureus
Mahen MRA, Taha RSI, Parmar AG, Hameed B.   +3 more
europepmc   +1 more source

Drugs induced Raynaud's phenomenon and underlying mechanism: a disproportionality analysis from the WHO pharmacovigilance database

Arthritis &Rheumatology, Accepted Article.
Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's Phenomenon (RP) and to explore their potential pathophysiological mechanisms through a mixed disproportionality/clustering analysis from the WHO pharmacovigilance database.
Alex Hlavaty, Loubna Dari, Jean‐Luc Cracowski, Matthieu Roustit, Charles Khouri   +4 more
wiley   +1 more source